Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II ex Vivo Gene Therapy Clinical Trial for RDEB Using Autologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral Vector

NCT04186650 is registered in ClinicalTrials.gov with Institut National de la Santé Et de la Recherche Médicale, France as lead sponsor.

NCT NCT04186650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04186650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II ex Vivo Gene Therapy Clinical Trial for RDEB Using Autologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral Vector
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 10, 2020
Completion date
June 9, 2027
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa dystrophica, recessive